Bob Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. He has pioneered the use of stem cells to treat a range of life-threatening diseases and has made transformative contributions in the field of tissue engineering.
His current positions include The Chairman, Founder, and CSO of Celgene Cellular Therapeutics, US, Academic Neurosurgeon at Cornell, US, a Non-executive Director of Myos Corporation, US and Provista Diagnostics, US, an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine, US, a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and of the scientific advisory board for the Archon X PRIZE for Genomics.
He is a Trustee of the Liberty Science Center and a Commissioner of Cancer Research by NJ Governor Christie, a member of the Board of Trustees of the J. Craig Venter Institute and was a recipient of the Thomas Alva Edison Award (2007, 2011), and The Fred J. Epstein Lifetime Achievement Award.
Bob authored over 90 issued and pending patents, over 100 published chapters, articles and abstracts and is most recognized for his discovery of placenta-derived pluripotent stem cells.